Santen Positioned for Further Growth in China Following Completion of Santen Vision Park

April 16, 2024, Osaka, Japan – Santen Pharmaceutical Co., Ltd. (hereinafter Santen) held a ceremony today to mark the completion of the construction phase of Santen Vision Park in Suzhou, Jiangsu Province, People’s Republic of China. The new factory, located in Suzhou Industrial Park, will address increasing demand in the country for prescription ophthalmic solutions while reinforcing the company’s production and supply structure in China.

Santen Vision Park, construction of which began in April 2021, is aimed at securing sufficient production capacity for innovative new production and established supply portfolio in the Chinese market. Production capacity of Santen Vision Park is expected to exceed 800 million bottles/annually (5mL), and Santen is targeting a 2027 start for commercial production following the commissioning, required qualification, and certification phases.

Santen Vision Park will be a smart facility, utilizing a data-driven scientific decision-making approach to promote efficiency and traceability. The facility will feature an integrated platform for real-time, visualized data across all operational facets, enhancing both information flow and management efficiency. At the heart of its production capabilities will be an advanced Blow-Fill-Seal technology and intelligent filling system. Logistics will be supported by automated guided vehicles and rail guided vehicles, enabling efficient, flexible, and scalable operations.

Representatives from Santen Global, Santen China, the Suzhou Government and local partners attended a ceremony the same day to mark the facility’s completion. “Today marks an important milestone but also a brand-new beginning. Santen Vision Park will ensure that we have capacity to meet the growing and diverse needs of Chinese patients, and contribute to eye health in China,” said Mark Dawson, Chief Product Supply Officer at Santen.

As a specialized company dedicated to eye health, Santen aspires to realize “Happiness with Vision” by providing valuable products and services to consumers, patients, and medical professionals around the world. To this end, a stable supply of high-quality products is of the utmost importance. Santen is striving to maximize the value of its assets and pursue a supply system that achieves high productivity, aligning with the realization of the company’s Medium-Term Management Plan announced in May 2023.

About Santen
As a specialized company dedicated to eye health, Santen aspires to contribute to the realization of “Happiness with Vision” by providing products and services to patients, consumers, and medical professionals around the world. Since its establishment, and guided by its CORE PRINCIPLE, “Tenki ni sanyo suru,” Santen has been committed to helping people maintain and improve their eye health for more than 130 years. Santen is engaged in the global research and development, manufacturing, and sales and marketing of pharmaceutical products in the field of eye care, supporting the eye health of approximately 50 million people in more than 60 countries and regions worldwide. Santen’s mission is to provide essential and significant value to patients and society in the prevention, diagnosis, and treatment of eye diseases through products and services created from its expertise in the ophthalmology field and from the patient's perspective. To create a future in which as many patients as possible can lead happy and fulfilling lives, Santen is committed to doing its utmost to realize a society in which people around the world can experience “Happiness with Vision.”
For more information, please visit Santen’s website https://www.santen.com/en.

Contact
Corporate Communications
Santen Pharmaceutical Co., Ltd.
E-mail: communication@santen.com